Shots:

• Exicure to receive a $20M up front and will be eligible to receive ~$1B in option exercise fees and milestones along with royalties- if Ipsen exercises its option
• Exicure will be responsible for the discovery and pre-clinical development activities while Ipsen will lead further development and commercialization of the licensed product after exercising the option
• Ipsen obtains exclusive options to license SNA based therapeutics for Huntington’s disease and Angelman syndrome based on two collaboration programs

 to   | Ref: Ipsen | Image: Business Wire